Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Berberine tannate is a salt form of the isoquinoline alkaloid berberine, combined with tannic acid. It is primarily utilized as an active pharmaceutical ingredient (API) in the treatment of gastrointestinal disorders, particularly diarrhea and gastroenteritis. The tannate salt form is often preferred in oral formulations to mitigate the intense bitterness of berberine and potentially provide a more controlled release within the digestive tract. Berberine itself exhibits a broad spectrum of biological activities, including antimicrobial, anti-inflammatory, and metabolic regulatory effects, often attributed to its ability to activate adenosine monophosphate-activated protein kinase (AMPK) and interact with DNA and RNA. Inga Pharmaceuticals is a notable manufacturer of this bulk ingredient.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on berberine tannate.